Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition
Collazo-Lorduy A, Castillo-Martin M, Wang L, Patel V, Iyer G, Jordan E, Al-Ahmadie H, Leonard I, Oh W, Zhu J, McBride R, Cordon-Cardo C, Solit D, Sfakianos J, Galsky M. Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. European Urology 2016, 70: 771-775. PMID: 27178450, PMCID: PMC5489411, DOI: 10.1016/j.eururo.2016.04.037.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAntineoplastic AgentsCetuximabColonic NeoplasmsDrug Resistance, NeoplasmErbB ReceptorsExome SequencingFemaleHumansMaleMitogen-Activated Protein KinasesMutationNeoplasm MetastasisNeoplasm StagingPharmacogenomic TestingProto-Oncogene Proteins p21(ras)Signal TransductionUrinary Bladder NeoplasmsConceptsMetastatic urachal cancerUrachal cancerTargeted exome sequencingUrachal carcinomaEGFR amplificationColorectal cancerMitogen-activated protein kinaseParaffin-embedded tumor specimensMetastatic urachal carcinomaMonoclonal antibodiesSingle-agent cetuximabTreated with cetuximabEpidermal growth factor inhibitionEpidermal growth factor receptorLimited treatment optionsWild-type KRASPrimary tumor tissuesGrowth factor inhibitionGrowth factor receptorWhole-exome sequencingEnteric adenocarcinomaCetuximab sensitivitySystemic therapyTumor specimensAggressive malignancy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply